Nicole Gordon Takes the Helm at Jnetics

Jnetics is pleased to announce the appointment of Nicole Gordon as its new Chief Executive Officer. Nicole, formerly Executive Director of Jewish Child’s Day, returns to the UK having spent a year in California with her family where she continued with her charity work.

Nicole has worked within the Jewish Community at a senior level for 15 years. Prior to JCD, she ran the Malki Foundation after spending 5 years at the Jewish Chronicle in a variety of marketing roles. Her earlier career was in blue chip consumer marketing with both Diageo and Chanel.

Nicole said “I am so excited to take the CEO role at Jnetics. It is an outstanding charity with a clear and distinct proposition that makes it very different. I studied Biochemistry and Immunology at University and undertook a two-year research post developing a vaccine against malaria in 3rd world countries, and I have always been passionately interested in genetic variation and hereditary disorders. I care hugely about the future of our community, and I feel this role, that addresses the important challenge of genetic disorders within the UK Jewish community, is tailor made for me.”

Tony Angel, Char of the Board of Trustees said “We are delighted to welcome Nicole as our new CEO. She brings a unique blend of experience in a leadership role and of working in the community, alongside a passion for and understanding of the scientific and medical background to our work.”

Nicole added “I was hugely impressed by the vision of the Board of Trustees, and my role is to work with them in taking Jnetics to the next level. We have a responsibility to the Jewish community to dramatically improve the understanding and management of Jewish genetic disorders, and, in particular, to ensure that nobody should ever have to endure the tragedy of having a child born with an utterly devastating yet wholly preventable recessive Jewish genetic disorders.”

Jnetics is the only cross- communal organisation in the UK dedicated to managing and preventing Jewish genetic disorders. Its GENEius, programme established a little over three years ago, aims to eliminate new cases of severe recessive Jewish genetic disorders in our community. Thousands of Jewish sixth form and university students, engaged couples and other young adults now have the knowledge to erase the risk of passing any of the severely debilitating, life shortening recessive genetic disorders that Jnetics screen for onto future generations.